Search Results - "Peacock, Nancy"

Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab by SPIGEL, David R, HAINSWORTH, John D, YARDLEY, Denise A, RAEFSKY, Eric, PATTON, Jeffrey, PEACOCK, Nancy, FARLEY, Cindy, BURRIS, Howard A, ANTHONY GRECO, F

“…PURPOSE Tracheoesophageal fistulae are rare complications of thoracic cancers and their treatments. Novel antiangiogenic agents in cancer treatment such as…”
Get full text

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute by Yardley, Denise A., Bosserman, Linda D., O’Shaughnessy, Joyce A., Harwin, William N., Morgan, Susan K., Priego, Victor M., Peacock, Nancy W., Bass, J. David, Burris III, Howard A., Hainsworth, John D.

“…Amplified PI3K/Akt/mTOR signaling is common in metastatic breast cancer (MBC). The mTOR inhibitor everolimus improves progression-free survival (PFS) when…”
Get full text

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer by STORNIOLO, Anna Maria, PEGRAM, Mark D, PANDITE, Lini, FLEMING, Ronald A, LEBOWITZ, Peter F, HO, Peter T. C, BURRIS, Howard A, OVERMOYER, Beth, SILVERMAN, Paula, PEACOCK, Nancy W, JONES, Suzanne F, LOFTISS, Jill, ARYA, Nikita, KOCH, Kevin M, PAUL, Elaine

“…The combination of lapatinib and trastuzumab has been observed to have a synergistic, antiproliferative effect against ErbB2-positive breast cancer cells in…”
Get full text

Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer by Yardley, Denise A., Shipley, Dianna L., Peacock, Nancy W., Shastry, Mythili, Midha, Rajiv, Priego, Victor M., Hainsworth, John D.

“…The purpose of the study is to evaluate the feasibility and efficacy of adding sunitinib to paclitaxel/carboplatin in the neoadjuvant therapy of patients with…”
Get full text

A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score by Yardley, Denise A., Peacock, Nancy W., Shastry, Mythili, Burris, Howard A., Bechhold, Rebecca G., Hendricks, Carolyn B., Yoshizawa, Carl N., Sing, Amy P., Hainsworth, John D.

“…Ixabepilone and the taxanes have similar activity in the first-line treatment of metastatic breast cancer, and ixabepilone is sometimes effective in…”
Get full text

Patient Perspectives on Breast Cancer Treatment Plan and Summary Documents in Community Oncology Care: A Pilot Program by BLINDER, Victoria S, NORRIS, Virginia W, PEACOCK, Nancy W, GRIGGS, Jennifer J, HARRINGTON, David P, MOORE, Anne, THERIAULT, Richard L, PARTRIDGE, Ann H

“…Although the routine use of treatment plans and summaries (TPSs) has been recommended to improve the quality of cancer care, limited data exist about their…”
Get full text

Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors by Jones, Suzanne F., Infante, Jeffrey R., Spigel, David R., Peacock, Nancy W., Thompson, Dana S., Greco, F. Anthony, McCulloch, William, Burris III, Howard A.

“…Romidepsin is a potent histone deacetylase inhibitor; preclinical studies showed potential synergy with the nucleoside analog gemcitabine. This phase 1 trial…”
Get full text

Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study by Gilmore, James W, Peacock, Nancy W, Gu, Anna, Szabo, Stephen, Rammage, Melissa, Sharpe, Joyce, Haislip, Sally T, Perry, Toni, Boozan, Tim L, Meador, Katherine, Cao, Xiting, Burke, Thomas A

“…Consensus guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) are variably implemented in practice. The purpose of this study was to…”
Get full text

A Phase II Trial of Neoadjuvant Gemcitabine, Epirubicin, and Docetaxel as Primary Treatment of Patients With Locally Advanced or Inflammatory Breast Cancer by Yardley, Denise A, Peacock, Nancy W, Dickson, Natalie R, White, Melissa B, Vázquez, Elizabeth R, Foust, John T, Grapski, Richard, Hendricks, Linda K, Scott, William L, Hainsworth, John D

“…Abstract Background Three-drug regimens containing gemcitabine, an anthracycline, and a taxane produce response rates of 70%-90% in patients with metastatic…”
Get full text

A Phase II Feasibility Trial of Dose-Dense Docetaxel Followed by Doxorubicin/Cyclophosphamide as Adjuvant or Neoadjuvant Treatment for Women with Node-Positive or High-Risk Node-Negative Breast Cancer by Yardley, Denise A, Burris, Howard A, Farley, Cindy P, Barton, John H, Peacock, Nancy W, Spigel, David R, Greco, F. Anthony, Hainsworth, John D

“…Abstract Purpose Dose-dense adjuvant chemotherapy with doxorubicin/cyclophosphamide (AC) followed by paclitaxel has improved results compared with standard…”
Get full text

Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US by Razavi, Pedram, Ahmed, Mehnaj, Roush, Ashley, Parikh, Rohan, Hitchens, Abigail, Shen, Sherry, Safonov, Anton, Jhaveri, Komal L., Robson, Mark E., Peacock, Nancy Walker, Ma, Yanjun, Santarsiero, Elizabeth Chertow, Ganapathy, Vaidyanathan, Shah, Rohan M., Amefule, Adaeze Q., Lteif, Agnes, Blakely, L. Johnetta

“…e12533 Background: Despite improved management of HR+/HER2− EBC, pts experience recurrences while on or up to decades after ending standard-of-care (SOC) ET…”
Get full text

Phase II trial of eribulin in patients who do not achieve pathologic complete response by Daniel, Brooke, Anz, Betrand, Peacock, Nancy, Molthrop, David C, Young, Robyn, Yardley, Denise A, Shroff, Sonalee K

“…Purpose Women with residual invasive breast cancer at the primary site or axillary lymph nodes following neoadjuvant chemotherapy have a high risk of…”
Get full text

Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC) by Yardley, Denise A, Young, Robyn R, Adelson, Kerin B, Silber, Andrea L, Kommor, Michael D, Najera, Jose E, Daniel, Davey B, Peacock, Nancy W, Shastry, Mythili, Hainsworth, John D, Burris, Howard A

“…Background: Treatment options for TNBC are limited by the lack of estrogen and progesterone receptors as well as the absence of HER2 overexpression. AR is…”
Get full text

Care coordination for oral oncolytics through pharmacy integration and cycle 1-day 1 documentation by Peacock, Nancy Walker, McCullough, Stacey, Crumb, Jared, Owens, Leah, Kaufman, Laura, Arrowsmith, Edward, Patton, Jeffrey, Taylor, Jack L., Lyss, Aaron J., Kelsey, Carolyn J., Senneke, Kimberly, Frailley, Susan A

“…Abstract only 260 Background: The growing number of oral oncolytic therapies (OOTs) necessitates a standardized EMR workflow that integrates pharmacy…”
Get full text

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC) by Yardley, Denise A., Young, Robyn R., Adelson, Kerin B., Silber, Andrea L., Najera, Jose E., Daniel, Davey B., Peacock, Nancy, Finney, Lindsey, Hoekstra, Susan J., Shastry, Mythili, Hainsworth, John D., Burris, Howard A.

“…AR is a targetable pathway with AR modulation inhibiting estrogen- and androgen-mediated cell proliferation. Orteronel is an oral, selective, nonsteroidal…”
Get full text

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy by Yardley, Denise A., Peacock, Nancy, Daniel, Brooke, Anz, Betrand, Molthrop, David C., Shroff, Sonalee K., Young, Robyn, Jankov, Aleksander, Vander Woude, Amy, Shastry, Mythili, Pasek, Johanna, DeBusk, Laura M., Hainsworth, John D.

“…Purpose Women with residual invasive breast cancer at the primary site or axillary lymph nodes following neoadjuvant chemotherapy have a high risk of…”
Get full text

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers by Bendell, Johanna C., Zakari, Ahmed, Lang, Evan, Waterhouse, David, Flora, Douglas, Alguire, Kathryn, McCleod, Michael, Peacock, Nancy, Ruehlman, Peter, Lane, Cassie M., Earwood, Chris, Shih, Kent

“…Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors. Methods: Patients received…”
Get full text

Abstract OT2-1-07: A phase II study with orteronel as monotherapy in patients with androgen receptor (AR) expressing metastatic breast cancer (MBC) by Yardley, Denise A, Jones, Suzanne F, Peacock, Nancy W, Shastry, Mythili, Young, Robyn R, Kallab, Andre M, Burris III, Howard A

“…Background: Androgen Receptor (AR) signaling is a new target present in and under evaluation in all breast cancer subtypes. AR expression is noted in 70%-90%…”
Get full text

Changes in adjuvant endocrine therapy over one year among postmenopausal women with early-stage breast cancer initiating aromatase inhibitors by LaMorte, Danielle Lindsay, Hartmann, Katherine E., Abramson, Vandana Gupta, Mayer, Ingrid A., Peacock, Nancy Walker, Cella, David, Castel, Liana Desharnais

“…Abstract only 11 Background: Aromatase inhibitors (AIs) are standard of care for adjuvant endocrine therapy (AET) to prevent recurrence of early stage breast…”
Get full text

Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial by Flinn, Ian W., Mainwaring, Mark, Peacock, Nancy, Shipley, Dianna, Arrowsmith, Edward, Savona, Michael R., Hainsworth, John D., Berdeja, Jesus G.

“…Abstract 2748 Mantle cell lymphoma (MCL) is a relatively rare but aggressive form of B-cell non-Hodgkin lymphoma (NHL) which is incurable with standard…”
Get full text